TheracosBio launches lowest cost SGLT2 inhibitor Brenzavvy

US drug developer TheracosBio today announced that Brenzavvy (bexagliflozin), an approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, is now available by prescription through the Mark Cuban Cost Plus Drug Company, a pharmacy benefit manager (PBM).

One 30-day supply of Brenzavvy is available for $47.85 plus shipping and handling, which TheracosBio says is the lowest price for any SGLT2 inhibitor on the market. In comparison, all other brand-name SGLT2 inhibitors on the market are priced at rates in the hundreds of dollars per month, with some 30-day prescriptions approaching $600 per month. TheracosBio’s business model is specifically designed to deliver effective medications for prevalent diseases while translating cost savings to patients.

TheracosBio secured US Food and Drug Administration approval for Brenzavvy in January this year. The company will compete with existing well-established products in this class, including Boehringer Ingelheim and Eli Lilly’s (NYSE: JNJ) Jardiance (empagliflozin), AstraZeneca’s (LSE: AZN) Farxiga (dapagliflozin), Johnson & Johnson (NYSE: JNJ) Invokana (canagliflozin) and Astellas Pharma (TYO: 4503) Suglat (ipragliflozin).